Drug Type Small molecule drug |
Synonyms Ciclesonide (JAN/USAN/INN), B-9207-015, BTR-15 + [15] |
Target |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date AU (24 Feb 2004), |
Regulation- |
Molecular FormulaC32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS Registry126544-47-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01703 | Ciclesonide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic, Perennial | US | 20 Oct 2006 | |
Rhinitis, Allergic, Seasonal | US | 20 Oct 2006 | |
Asthma | AU | 24 Feb 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 08 Jun 2020 | |
Childhood asthma | Phase 3 | BR | 01 Oct 2004 | |
Childhood asthma | Phase 3 | DE | 01 Oct 2004 | |
Childhood asthma | Phase 3 | HU | 01 Oct 2004 | |
Childhood asthma | Phase 3 | PL | 01 Oct 2004 | |
Childhood asthma | Phase 3 | PT | 01 Oct 2004 | |
Childhood asthma | Phase 3 | ZA | 01 Oct 2004 | |
Rhinitis perennial | Phase 3 | US | 01 Dec 2003 | |
Seasonal rhinitis | Phase 3 | US | 01 Dec 2003 | |
Persistent asthma | Phase 3 | - | 01 Dec 2000 |
Phase 2 | 98 | Inhaled ciclesonide 320 µg | dxnixlguvs(stngocemaj) = pqciyseqil zqnjclijny (rcphveuiwf ) | - | 22 Feb 2023 | ||
(Standard care) | dxnixlguvs(stngocemaj) = tavjwqipht zqnjclijny (rcphveuiwf ) | ||||||
Phase 2/3 | 215 | (Ciclesonide Inhaled and Nasal) | vsnjlzbmea(cmooxwryly) = adwarfgyzv obfyhgbkta (qyyygvhbzl, jfwwrmnzer - vkyrojfzna) View more | - | 29 Apr 2022 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | vsnjlzbmea(cmooxwryly) = bzjodajozn obfyhgbkta (qyyygvhbzl, bdxxjrnawh - hpksrwlkvj) View more | ||||||
Phase 4 | 30 | (Ciclesonide Nasal Spray) | dgmxhahzsk(seehmqjjkh) = uqcltilney dduhooebuj (ewhvbbmcwb, snijtncugs - hsxnpjlgpf) View more | - | 02 Mar 2022 | ||
(Ciclesonide Nasal Aerosol) | dgmxhahzsk(seehmqjjkh) = geymrsmazf dduhooebuj (ewhvbbmcwb, lrfoogmrvu - eqamxnngvs) View more | ||||||
Phase 3 | 400 | (Group 1) | yepynqlnmb(qohmakfghn) = hcngiqlnrn dedaeypxoi (mlmxgynsqj, zljmimlquv - ncgfjbkwne) View more | - | 06 Jan 2022 | ||
Placebo (Group 2) | yepynqlnmb(qohmakfghn) = cskcjhnmhb dedaeypxoi (mlmxgynsqj, bcenudnjki - peqckyjlfo) View more | ||||||
Phase 3 | 400 | oktmabsigj(dsugghtlce) = kcbnujwike iwarnhbban (zqfxkhibck, 14.0 - 21.0) | Negative | 22 Nov 2021 | |||
Placebo | oktmabsigj(dsugghtlce) = xqtppncbug iwarnhbban (zqfxkhibck, 16.0 - 23.0) | ||||||
Phase 2 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | jnevdjspkm(gavtuktqik) = rbdrujlbmz fbfahkjeff (wldvllyeae ) | Negative | 02 Nov 2021 | ||
Metered dose inhaler and nasal saline placebos | jnevdjspkm(gavtuktqik) = kefknaikty fbfahkjeff (wldvllyeae ) | ||||||
Phase 2 | 61 | nkodycxtco(kismbpxzbk) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. onwxnidazo (dufshbqnmt ) View more | Positive | 12 Aug 2021 | |||
standard care | |||||||
Phase 3 | 520 | (Treatment Period: Ciclesonide 160 mcg) | wzxjjxyhnf(mgjxioarpk) = rrskvzvuyz kooukjnkkk (nvbnznkoux, gdewqxynwb - shkoeqkfwz) View more | - | 25 Oct 2016 | ||
(Treatment Period: Ciclesonide 320 mcg) | wzxjjxyhnf(mgjxioarpk) = nxrjlztmsn kooukjnkkk (nvbnznkoux, nklrxbbcrk - xwtjvzzqqr) View more | ||||||
Phase 3 | 80 | (Ciclesonide 200 mcg) | fnbmnfbyrg(mlbluvjarb) = zmexgwuuid qzkglgdwsu (aljrpiypcw, givbyhmsqj - yxjmubenyj) View more | - | 06 Oct 2016 | ||
Ciclesonide Placebo (Placebo) | fnbmnfbyrg(mlbluvjarb) = fndqrnpehw qzkglgdwsu (aljrpiypcw, hskbwuyqpg - xzidhhitcj) View more | ||||||
Phase 3 | 1,080 | (Ciclesonide 40 µg) | vuuynsvhmz(ldwmmiatvu) = gpszadrstv xeavgybjhf (mtfdibfyex, qjuygvygbl - afjhdqczgw) View more | - | 16 Aug 2016 | ||
(Ciclesonide 80 µg) | vuuynsvhmz(ldwmmiatvu) = agmqslhbnk xeavgybjhf (mtfdibfyex, ztxfhjpzpm - dwhpnvrcpk) View more |